Fusafungine (
INN
Inns are generally establishments or buildings where travelers can seek lodging, and usually, food and drink. Inns are typically located in the country or along a highway; before the advent of motorized transportation they also provided accommo ...
), also known as fusafungin, is an active agent used in
antibiotics for treatment of
nasal and
throat infection. It also possesses
anti-inflammatory
Anti-inflammatory is the property of a substance or treatment that reduces inflammation or swelling. Anti-inflammatory drugs, also called anti-inflammatories, make up about half of analgesics. These drugs remedy pain by reducing inflammation as o ...
properties. Fusafungine is a mixture of
enniatin cyclohexadepsipeptides made up of alternating
D-α-hydroxyvaleric acid and
L-''N''-methylamino acid residues, produced by the
ascomycete ''
Fusarium lateritium'', and marketed by
Servier
Servier Laboratories (French: Laboratoires Servier, often abbreviated to Servier) is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes).
The consolidated turnover for the 2018 ...
under the trade names Locabiotal, Bioparox, and Locabiosol.
According to a pooled analysis study done in the UK for the efficacy of fusafungine in
rhinopharingitis, it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo.
In February 2016, the
European Medicines Agency recommended the withdrawal of fusafungine from the market due to rare but severe allergic reactions (mainly
bronchospasm
Bronchospasm or a bronchial spasm is a sudden constriction of the muscles in the walls of the bronchioles. It is caused by the release (degranulation) of substances from mast cells or basophils under the influence of anaphylatoxins. It causes di ...
s).
References
Antimicrobial peptides
Depsipeptides
{{respiratory-system-drug-stub